Andrea C. Gabrielli - Publications

Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC).

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: February 27, 2025

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 07, 2023

Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis.

Journal: Frontiers in immunology

Published: October 17, 2022

Tocilizumab in COVID-19 interstitial pneumonia.

Journal: Journal of internal medicine

Published: September 23, 2020

Bi-stability of SUDR+K model of epidemics and test kits applied to COVID-19.

Journal: Nonlinear dynamics

Published: April 24, 2020

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Journal: Scandinavian journal of rheumatology

Published: October 10, 2017

European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 15, 2017

European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 15, 2017

Certolizumab pegol for the treatment of psoriasis.

Journal: Expert opinion on biological therapy

Published: February 07, 2017

Recommendations for the management of biofilm: a consensus document.

Journal: Journal of wound care

Published: June 12, 2016

Alterations of ROS pathways in scleroderma begin at stem cell level.

Journal: Journal of biological regulators and homeostatic agents

Published: March 16, 2013